echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Phase II clinical success of eprenetapopt+azacitidine in the treatment of TP53 mutant MDS and AML

    Phase II clinical success of eprenetapopt+azacitidine in the treatment of TP53 mutant MDS and AML

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Aprea Therapeutics recently announced the positive results of a phase 2 clinical trial that is evaluating eprenetapopt (APR-246) in combination with azacitidine (AZA) for TP53 mutant myelodysplastic syndrome (MDS) and acute myelodysplastic syndromes.


    In addition to eprenetapopt, Aprea also has a drug APR-548, which is a new generation of small molecule p53 reactivator, which shows high oral bioavailability in TP53 mutant cancer cell lines, and has enhanced efficacy compared with eprenetapopt.


    Original source: Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML

    Original title: New drug for p53 target! eprenetapopt+azacitidine in the treatment of TP53 mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a significant effect!

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.